In May 2014, AC Immune signed its first diagnostic partnership, with Life Molecular Imaging SA (formerly Piramal Imaging SA). This exclusive worldwide out-licensing agreement for a Tau protein Positron Emission Tomography (PET) tracer PI-2620 supporting the early diagnosis and clinical management of Alzheimer’s disease and other Tau-related disorders, such as progressive supranuclear palsy (PSP). The agreement includes upfront and sales milestone payments totaling up to EUR 160 million, plus royalties.
In January 2025, Lantheus Holdings announced the acquisition of Life Molecular Imaging Ltd., which was completed in August 2025.